ARTICLE | Company News

Priority Review for Marathon's DMD therapy

August 10, 2016 7:00 AM UTC

Marathon Pharmaceuticals LLC (Northbrook, Ill.) said FDA accepted for filing and granted Priority Review to an NDA for deflazacort ( MP-104) to treat Duchenne muscular dystrophy. The company said it expects a decision from FDA in February 2017.

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. In April, Marathon presented Phase III results showing that the candidate improved average muscle strength and performance on timed functional tests vs. placebo. ...